1Nelson BH, Willerlord OM. Biology of the interleukin-2 receptor [J]. Adv Immunol, 1998, 70: 1-8].
2Belz GT.Masson F. Interleukin-2 tickles T cell memory [J]. Immunity, 2010, 32(1) : 7-9.
3Stauber OJ, Oebler EW, Horton PA, et al, Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor [J]. Proc Natl Acad Sci USA, 2006, 103 ( 8 ) : 2788-2793.
4Malek TR, Castro 1. Interleukin-2 receptor signaling: at the interface between tolerance and immunity [J]. Immunity, 2010, 33 (2): 153-165.
5Shevach EM. Application of IL-2 therapy to target T regulatory cell function [J]. Trends Immunol, 2012, 33 (\2) : 626-632.
6Wang X, Lupardus P, Laporte SL, et .a. Structural biology of shared cytokine receptors [J]. Annu Rev Immunol, 2009, 27: 29-60.
7Kalia V, Sarkar S, Subramaniam S, et al. Prolonged interleukin- 2Ralpha expression on virus-specific C08 + T cells favors terminaleffector differentiation in vivo [J]. Immunity, 2010, 32 ( 1 ) : 91- 103.
8Konda R, Sakai K, Ota S, Soluble interleukin-2 receptor in children with reflux nephropathy [J]. J Urnl, 1998, 159 ( 2 ) : 535-539.
9Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy [J]. Nat Rev Immunol, 2010,10(5): 317-327.
10Bien E, Balcerska A, Serum soluble interleukin 2 receptor alpha in human cancer of adults arid children:' a review [J]. Biomarkers, 2008, 13 (1 ) : 1-26.
